- Valeant's Phase 3 trial results compared its latanoprostene bunod with the generic timolol. There is no proof it is better than the market-leading prostaglandin analogs because it wasn't compared.
- Prostaglandin analogs such as latanoprost, bimatoprost, travoprost are well-established drugs known to be more effective than timolol. They have been around for many years.
- Valeant claims its latanoprostene bunod (Vesneo) will get peak sales of $500 million to $1 billion. Valeant did not compare Vesneo to any prostaglandin analog in the clinical trial.
- Peak sales estimates by pharma companies are simple and unscientific. They can be off by a huge factor.
- How would Valeant's drug achieve such a high peak sales number when as effective or more effective drugs have gone generic?